Incyte’s goal is to become a leading global biopharmaceutical company. Incyte is a company founded on the premise that investment in good science and the rigorous pursuit of R&D excellence can translate into new medicines that can positively affect patients’ lives.Our therapeutic focus is primarily oncology. We believe the future of cancer treatment lies with immune therapies, which seek to recruit the patient’s own immune system to tackle cancer, and with targeted therapies, which aim to block the effects of cancer-causing mutations. In addition to our marketed products, we have a broad and diversified selection of clinical candidates in our growing portfolio, from both our own laboratories and from partners via licensing transactions.
|Bank Name||Incyte Corporation|
|Industry||Biotechnology: Commercial Physical|
|Chairman||Mr. Hervé Hoppenot|
|CEO||Mr. Hervé Hoppenot|